IP Library Granted Patent US 11,672,855
Granted Patent B2
US 11,672,855 · App. 17/035,451 · Granted Jun 13, 2023

MDCK suspension cell lines in serum-free, chemically-defined media for vaccine production

Inventors: Jenny Bang (Santa Ana, CA); Hsiao-Tzu Ni (Santa Ana, CA); Alan Yung-Chih Hu (Zhunan Town, TW); Tsai-Chuan Weng (Zhunan Town, TW)
Assignees: NATIONAL HEALTH RESEARCH INSTITUTES; FUJIFILM IRVINE SCIENTIFIC, INC.
A61K39/145A61K39/12C12N5/0686C12N7/00C12N15/8509A61P31/16C12N2015/8518C12N2500/90C12N2500/99C12N2511/00C12N2513/00C12N2517/02C12N2760/16034C12N2760/16051C12N2760/16134C12N2760/16151C12N2760/16251
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,672,855
App. No.
17/035,451
Granted
Jun 13, 2023
Kind
B2
Abstract

Disclosed is an adapted Madin-Darby canine kidney cell line capable of suspension culture in the absence of serum, and a chemically-defined medium for culture of the adapted MDCK cell line. Further disclosed are culture methods for growing the adapted MDCK cell line and methods for producing a vaccine from the adapted MDCK cell line grown in the chemically-defined medium.

Claims (9)

1. A cell culture comprising isolated adapted Madin-Darby canine kidney (MDCK) cells deposited as DSM ACC3309 with Leibniz-Institut DSMZ-Deutsche Sammlung von Mikro-organismen and Zellkulturen GmbH and a growth medium that comprises from about 20 mM to about 30 mM glucose.

2. The cell culture of claim 1 , wherein the growth medium is a chemically-defined and animal component free medium.

3. A method of producing an influenza virus for vaccine production, comprising contacting isolated adapted Madin-Darby canine kidney (MDCK) cells deposited as DSM ACC3309 with Leibniz-Institut DSMZ-Deutsche Sammlung von Mikro-organismen and Zellkulturen GmbH with a growth medium, infecting the isolated adapted MDCK cells with an influenza virus, and harvesting the influenza virus.

4. The method of claim 3 , wherein the growth medium is a chemically-defined and animal-component-free medium.

5. The method of claim 3 , wherein the growth medium comprises from about 20 mM to about 30 mM glucose.

6. The method of claim 3 , further comprising preparing a vaccine from the harvested influenza virus.

7. The method of claim 6 , wherein the vaccine is a human vaccine.

8. The method of claim 6 , wherein the prepared vaccine comprises a plurality of the harvested influenza viruses.

9. The method of claim 8 , wherein the plurality of harvested influenza viruses maintain antigenicity.

Assignments (4)
CHANGE OF NAME Recorded Dec 15, 2025
From: FUJIFILM IRVINE SCIENTIFIC, INC.
To: FUJIFILM BIOSCIENCES INC.
Reel/Frame 073950/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2023
From: HU, ALAN YUNG-CHIH; WENG, TSAI-CHUAN
To: NATIONAL HEALTH RESEARCH INSTITUTES
Reel/Frame 062655/0138 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2023
From: BANG, JENNY; NI, HSIAO-TZU
To: IRVINE SCIENTIFIC SALES COMPANY, INC.
Reel/Frame 062655/0616 →
CHANGE OF NAME Recorded Feb 10, 2023
From: IRVINE SCIENTIFIC SALES COMPANY, INC.
To: FUJIFILM IRVINE SCIENTIFIC, INC.
Reel/Frame 062703/0158 →
Continuity (3)
Continuation 15771029
Provisional Application 62248954 · Oct 30, 2015
Related Publication 20210008194A1 · Jan 14, 2021